Report
Louis AZAIS
EUR 110.87 For Business Accounts Only

Analyse court terme - GILEAD SCIENCES : Les prix dépassent la moyenne mobile, c'est un signal de force.

La résistance vient d'être franchie, la tendance devient positive puisque nous avons maintenant une succession de sommets et de creux ascendants. Le prochain objectif est à 75,60 $. Le niveau d'invalidation est sous 66,20 $.

Arguments :
- Les prix dépassent la moyenne mobile, c'est un signal de force.
Underlying
Gilead Sciences Inc.

Gilead Sciences is a research-based biopharmaceutical company that discovers, develops and commercializes medicines. The company's primary areas of focus include viral diseases, inflammatory and fibrotic diseases and oncology. The company's products include: Biktarvy for the treatment of HIV-1 infection in certain patients; Vosevi?, a single tablet regimen of sofosbuvir, velpatasvir and voxilaprevir for the re-treatment of chronic hepatitis C virus infection in adults; Vemlidy? for the treatment of chronic hepatitis B virus infection in adults with compensated liver disease; and Yescarta (axicabtagene ciloleucel) for the treatment of adult patients with relapsed or refractory large B-cell lymphoma.

Provider
Day By Day
Day By Day

​​DayByDay is an independent research company providing global macro and single stock analysis, recommendation and allocation based purely on behavioural finance methods. Those include long term cycle analysis, sentiment analysis, and technical trigger. DayByDay serves all clients in need of practical and precise publications to make effective market decisions, on any time horizon, from a few hours to a few years.

Analysts
Louis AZAIS

Other Reports on these Companies
Other Reports from Day By Day

ResearchPool Subscriptions

Get the most out of your insights

Get in touch